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Longitudinal Health Insurance Database during 2000-2008. VTE cases were iden-
tified based on the disease diagnosis coding and anticoagulant prescription or 
surgical thrombectomy procedure from the claims of inpatient or emergency 
care. Using risk set sampling, ten controls were selected for each case, matched 
on age (± 5 years), entry date (± 180 days), cancer diagnosis and major surgery 
procedure. Use of antipsychotics classified into typical antipsychotics (TAPs) and 
atypical antipsychotics (AAPs) was evaluated in the 365 days prior to an index 
date. Confounding was adjusted using a summary risk score for VTE during condi-
tional multiple logistic regressions. Results: A total of 1,616 VTE cases and 16,026 
controls were identified. Any use of TAPs was associated with a 1.26-fold (95% CI, 
1.06-1.50) increased VTE risk compared with nonuse. The risk varied depending 
on specific TAP-use scenarios, with the greatest risk being observed for parenteral 
administration (ORadj, 1.82; 95% CI, 1.14-2.91), followed by high-average-daily dose 
(> 5 mg of olanzapine-equivalent dose; ORadj, 1.75; 95% CI, 1.23-2.50), long-term 
use (> 30 days; ORadj, 1.59; 95% CI, 1.17-2.17), and current use of TAPs (ORadj, 1.54; 
95% CI, 1.15-2.07). Conversely, the insignificant association between AAP use and 
VTE risk was found and remained across the abovementioned drug-use condi-
tions. ConClusions: Use of TAPs but not AAPs is associated with an increased 
VTE risk. Health care professionals should be vigilant about VTE development in 
postmenopausal women receiving TAPs, especially for those receiving parenteral 
administration or high doses of TAPs.
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objeCtives: Simvastatin is an antihyperlipidemic agent used to lower serum cho-
lesterol. Simvastatin has been associated with rhabdomyolysis, a rare but potentially 
life-threatening Adverse Drug Event (ADE). Recently, the FDA created a black box 
warning limiting use of simvastatin at higher doses. The objective of this study was 
to evaluate the data in the FDA Adverse Event Reporting System (FAERS) to describe 
and profile the cases that led to this decision. Methods: A retrospective analy-
sis of all domestic and foreign reports of simvastatin-associated rhabdomyolysis 
between October 1997 and September 2011 was conducted using FAERS database. 
The frequency of the following outcomes was examined: congenital anomaly, death, 
life-threatening reaction, hospitalization, disability, others and required interven-
tion. The percentage of role codes (primary suspect, secondary suspect, concomitant 
drug, or interacting drug) was analyzed. Separate analysis was conducted to report 
frequency of doses associated with rhabdomyolysis. Drug dosages associated with 
both ADEs and specifically rhabdomyolysis were evaluated. Results: A total of 
3,014,229 simvastatin-associated reports were identified over a 14-year period in 
the FAERS database. Hospitalization occurred in 41.1% and death was reported in 
8.16% of the cases. Remarkably, 40.4% of ADE were reported for the 40mg dose and 
13.4% for the 80mg dose. Simvastatin was designated as concomitant in 73.6% and 
as a secondary suspect in 16.0% of the cases. A total of 25,701 reports of simvastatin-
associated rhabdomyolysis were reported. Of these, 6,673 rhabdomyolysis reports 
had dose information avaialble. Whereas, 44.1% were associated with the 40 mg 
dose; 26.7% were reported for 80mg dose. ConClusions: Simvastatin-associated 
ADE were demonstrated in the FAERS database with severe clinical outcomes includ-
ing hospitalization and death. The increased risk associated with higher simvastatin 
doses provides evidence to support the FDA’s black box warning.
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objeCtives: Beta-blockers remain important for secondary prevention after 
myocardial infarction (MI). Despite recommendations in clinical guidelines, the 
potential for poor glycemic control and difficulties in identifying warning signs 
of hypoglycemia limit their utilization in patients with type 2 diabetes (T2DM). To 
date, limited research evaluated differences in safety and efficacy based on differ-
ences in pharmacologic properties of beta-blockers. This study evaluated factors 
predicting post-MI beta-blocker utilization among T2DM patients. Methods: A 
retrospective cohort of employed, commercially insured individuals with depend-
ents was developed using de-identified patient enrollment files, medical claims, 
and pharmacy claims from 2007-2009. Inclusion criteria: (1) T2DM, (2) ≥ 18 years 
old, (3) continuous eligibility, (4) MI. Exclusion criteria: (1) females prescribed 
metformin exclusively without T2DM diagnosis codes, (2) < 6 months eligibil-
ity pre-MI, (3) MI before first T2DM date, (4) beta-blocker use pre-MI, (5) lack of 
comorbidity data. Bivariate statistics compared new beta-blocker users to non-
users. Multivariate logistic regression with odds ratios (OR) and 95% confidence 
intervals (95%CI) with manual backwards elimination was used to evaluate demo-
graphic characteristics and comorbidities as predictors of post-MI beta-blocker 
exposure. Results: Beta-blockers were used in 104 (28.5%) of the cohort with 
68.3% and 30.8% of new users receiving cardioselective and alpha-blocking beta-
blockers, respectively. Congestive heart failure (CHF) without hypothyroidism [OR: 
0.42; 95%CI: 0.18-0.95], cardiac arrhythmia without renal failure [OR: 0.46; 95%CI: 
0.23-0.92], hypothyroidism without CHF [OR: 0.17; 95%CI: 0.05-0.57], and renal 
failure without cardiac arrhythmia [OR: 0.23; 95%CI: 0.07-0.71] were statistically 
significant predictors of beta-blocker utilization. ConClusions: Our study evalu-
ated post-MI beta-blocker use in T2DM patients. We showed that T2DM patients 
with CHF, arrhythmias, hypothyroidism, or renal failure were less likely to receive 
beta-blockers post-MI. Although the results might not apply to older populations, 
our results support the need for further investigation to determine whether more 
T2DM patients could benefit from beta-blocker treatment post-MI.
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objeCtives: To better understand the ischemic stroke population with respect to 
atrial fibrillation (AF), oral anticoagulation (OAC) usage, and second stroke rates 
as a function of baseline CHADS2 and CHA2DS2-VASc risk scores. Methods: The 
population consists of all patients in the Truven Health MarketScan® Commercial 
and Medicare Supplemental Databases between 01/01/2008 and 12/31/2011 with 
an index ischemic stroke event and data available ±12 months around the index 
event. CHADS2 and CHA2DS2-VASc risk scores were derived from diagnosis codes, 
procedure codes, and prescription drug usage within 12 months prior to the index 
stroke. Results: A total of 174,318 patients (age 66.6±15.4 years, 54.4% female) 
were included. Among these, 11.9% had an AF diagnosis and/or antiarrhythmic drug 
usage within the 12 months prior to their index stroke. AF rates rose from 2.4% to 
39.9% as baseline CHADS2 scores increased and from 2.0% to 41.6% with increasing 
CHA2DS2-VASc scores. Only 9.6% of patients were on OAC in the year prior to their 
index stroke (3.7% to 27.4% by increasing CHADS2 score; 3.2% to 28.1% by increasing 
CHA2DS2-VASc score), and 48.9% of patients with AF were on OAC. Just 5.3% had new 
AF diagnosed within 12 months after their index stroke. The rate of second stroke 
in the year after the index stroke was 35.0% (29.5% to 39.2% and 29.2% to 39.3% by 
increasing CHADS2 and CHA2DS2-VASc scores, respectively). ConClusions: Over 
one-third of all surviving stroke patients experienced second strokes in the year 
following their first stroke. Given the low rate of newly diagnosed AF, this suggests 
that undiagnosed AF may be an important contributor to the high recurrent stroke 
rate. Further study is required to determine if more rigorous post-stroke arrhythmia 
monitoring can lead to increased AF detection and OAC utilization, thus resulting 
in a reduction in recurrent stroke.
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objeCtives: It is frequently stated that records for reimbursement purposes may 
show higher mortality rates than what actually occurs. Among other causes, it may 
occur out of intentional and unethical misuse of the register (e.g. by including only 
severe cases) or due to lack of knowledge on how to register the data. The aim of the 
study was to evaluate the accuracy of a public registry system concerning hospital 
mortality in coronary artery bypass surgery (CABS). Methods: The hospital cohort 
is composed by a retrospective cohort sample of all adults undergoing CABS on the 
State of Rio de Janeiro, Brazil, from January to December 2007. One Cohort obtained 
the data directly in the hospitals (in-hospital mortality) through chart review using 
a standardized electronic form. The other cohort (Registry cohort) included data 
obtained in the Brazilian Registry of hospital admissions systems (SIH / SUS). To cal-
culate the 30-day mortality, data were added through probabilistic linkage resorting 
to software RecLink 3. The rates comparisons were calculated using the Chi square 
test. Results: Were included in the registry cohort 18,080 patients submitted to 
CABS with 1,028 deaths and in the hospital cohort 231 patients with 26 deaths. The 
median age of the hospital cohort was 68.6 years old; 68.4% male, 63.2% were elective 
surgery. The hospital cohort showed higher mortality rate (11.3%) when compared 
with the registry cohort (6.22 %) with significant p value (< 0.05). ConClusions: 
The surgical mortality was high both in the registry and in the hospital cohort. 
Comparing the two forms of data collection, it shows that the mortality rate is even 
higher when collected directly from the hospitals. It can be explained by a selection 
bias of patients for inclusion in the registry. The use of secondary data for economic 
analysis may lead to an underestimation of the mortality rates in CABS.
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objeCtives: To compare effectiveness of initiation of different statins on LDL-C 
reduction among high cardiovascular-risk patients. Methods: Patients aged ≥ 18 
years and newly initiating statin therapy (rosuvastatin, atorvastatin, simvastatin, or 
pravastatin) were identified from the HealthCore Integrated Research Environment 
(HIRE) from 1/1/2007–2/28/2013. Patients were required to have ≥ 2 LDL-C values 
(one pre- and post statin initiation). Patients were classified as high risk (coronary 
heart disease [CHD] or CHD risk equivalent) based on NCEP ATP III guidelines and 
were propensity score matched on several baseline characteristics. Absolute change 
from baseline to most recent LDL-C values obtained in the follow-up period and 
proportion of patients attaining 50% reduction in LDL-C were compared between 
rosuvastatin versus the other statins grouped together and versus atorvastatin 
alone. Results: There were 625 matched high-risk patients in both the rosuvas-
tatin versus the overall group and 544 in both the rosuvastatin versus atorvastatin 
cohorts. Average follow-up was 259 (rosuvastatin) vs. 263 (overall) days and 264 
(rosuvastatin) vs. 239 (atorvastatin) days. Mean baseline LDL-C value was 130 mg/
dl (rosuvastatin) vs. 128 mg/dL (overall) and 131 mg/dl (rosuvastatin) vs. 126mg/dL 
(atorvastatin). Average daily dose was 10 mg for rosuvastatin, 26 mg for the overall 
group, and 21 mg for atorvastatin. Absolute reduction in LDL-C was higher for the 
rosuvastatin group compared to either the overall group (52 vs. 43 mg/dL; p< 0.0001) 
or the atorvastatin group (53 vs. 47 mg/dL; p= 0.0005). Proportion of patients attain-
ing 50% reduction in LDL-C was significantly higher for the rosuvastatin versus the 
